Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Cell Research - September 23, 2021 Category: Cytology Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Hematopoietic Recovery using Multi-Cytokine Therapy in 8 Patients Presenting Radiation-Induced Myelosuppression after Radiological Accidents
Radiat Res. 2021 Sep 23. doi: 10.1667/RADE-21-00169.1. Online ahead of print.ABSTRACTTreatment of accidental radiation-induced myelosuppression is primarily based on supportive care and requires specific treatment based on hematopoietic growth factors injection or hematopoietic cell transplantation for the most severe cases. The cytokines used consisted of pegylated erythropoietin (darbepoetin alfa) 500 IU once per week, pegylated G-CSF (pegfilgrastim) 6 mg × 2 once, stem cell factor 20 μg.kg-1 for five days, and romiplostim (TPO analog) 10 μg.kg-1 once per week, with different combinations depending on the accidents. A...
Source: Radiation Research - September 23, 2021 Category: Physics Authors: Marc Benderitter Eduardo Herrera-Reyes Yvan Gigov Bertrand Souleau Jean Christelle Huet Fran çois Trompier Thierry Fagot Eric Gr égoire Jean Val ère Malfuson Johanna Konopacki-Potet Elena Buglova Jean-Jacques Lataillade Radia Tamarat Patrick Gourmelon Source Type: research
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)
ConclusionRoxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4 months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies. (Source: Advances in Therapy)
Source: Advances in Therapy - September 19, 2021 Category: Drugs & Pharmacology Source Type: research
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Conclusion: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 16, 2021 Category: Neurology Source Type: research
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Conclusion: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.Am J Nephrol (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - September 16, 2021 Category: Neurology Source Type: research
Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?
AbstractPurpose of the ReviewIn this review paper, we examine the latest evidence regarding the use of iron supplementation, erythropoiesis-stimulating agents (ESAs), and blood transfusions as therapeutic targets for anemia to mitigate morbidity and mortality in patients with cardiovascular disease.Recent FindingsIntravenous ferric carboxymaltose (FC) injections in heart failure (HF) have resulted in improved self-reported patient symptoms; higher exercise capacity, as measured by 6-min walk test distance in anemic patients; and lower re-hospitalization rates in iron deficient patients. Darbepoetin alfa has shown evidence ...
Source: Current Atherosclerosis Reports - August 10, 2021 Category: Cardiology Source Type: research
Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat
Conclusion: This study confirmed that roxadustat therapy could alleviate the anemia of DD-CKD and NDD-CKD patients by raising the hemoglobin level and regulating iron metabolism, but increased serious incidences of treatment-emergent adverse events (TEAEs) in NDD-CKD patients. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 2, 2021 Category: Drugs & Pharmacology Source Type: research
